Rapid Neuro3D

Rapid Neuro3D is a software-based medical device designed to enhance the evaluation, documentation, and treatment planning of neurovascular lesions. It achieves this by utilizing artificial intelligence to process CT Angiography datasets, removing obfuscating structures to generate comprehensive 3D and 2D visualizations of the neurovasculature, validated for safety and performance against a predicate device.

A regulatory body has affirmed that iSchemaView, Inc. may market its medical device, Rapid Neuro3D. This determination was communicated to Patricia Setti-Laperch, a senior regulatory affairs director for the company, and signifies that the device is substantially equivalent to existing legally marketed devices for its indicated uses. The marketing of the device is subject to standard general controls and specific regulations applicable to its classification as a medical image management and processing system. Rapid Neuro3D is a software-based medical device designed to analyze CT Angiography (CTA) datasets of the head and neck. It utilizes artificial intelligence to remove bone, tissue, and venous vessels, providing comprehensive 3D and 2D visualizations of the neurovasculature. The software generates outputs such as maximum intensity projections (MIPS), volume renders (VR), and curved planar reformations (CPR) to aid physicians in evaluating, documenting, and planning treatment for identified lesions. This affirmation of marketability was supported by performance validation and software verification testing, which demonstrated the device's safety and performance in comparison to its predicate device, Rapid.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. What specific AI algorithms are employed by Rapid Neuro3D for bone, tissue, and venous vessel removal, and how do they compare to conventional methods?; What is the clinical impact of using Rapid Neuro3D's 3D and 2D visualizations and specific outputs (MIPS, VR, CPR) on diagnostic accuracy and treatment planning for neurovascular lesions?; How were the performance validation and software verification tests conducted, and what were the quantitative metrics of safety and performance used for comparison with the predicate device, Rapid?; Does Rapid Neuro3D offer any advantages in terms of speed, user interface, or integration with existing PACS/RIS systems compared to its predicate or other similar legally marketed devices?; What are the known limitations or potential biases of Rapid Neuro3D's AI-driven analysis, particularly in cases of complex or atypical neurovascular anatomy?